Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diclofenac transdermal second generation - Crescita Therapeutics

Drug Profile

Diclofenac transdermal second generation - Crescita Therapeutics

Alternative Names: Diclofenac sodium topical solution 2% w/w; MNK-395; NRI-1004; Pennsaid 2%; Pennsaid Gel; Pennsaid Plus; Pennsaid Viscous Solution

Latest Information Update: 16 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nuvo Research
  • Developer Gebro Pharma AG; Horizon Therapeutics plc; NovaMedica; Nuvo Research; Sayre Therapeutics
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Musculoskeletal pain

Most Recent Events

  • 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
  • 02 Apr 2019 Preregistration for Musculoskeletal pain in Austria (Transdermal, Gel)
  • 02 Apr 2019 Nuvo Pharmaceuticals anticipates decision of MAA by the Austrian Agency for Health and Food Safety (AGES) for Musculoskeletal pain, in the 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top